Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer as 3rd or Above Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2019
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Hutchison MediPharma
- 20 Jan 2018 Results of a post hoc analysis assessing quality of life (QoL) using a Q-TWiST analysis from this trial presented at the 2018 Gastrointestinal Cancers Symposium
- 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2015 Results published in a Hutchison China MediTech media release.